SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

Search

BioMerieux

Cerrado

SectorSalud

119 1.97

Resumen

Variación precio

24h

Actual

Mínimo

115.8

Máximo

119.9

Métricas clave

By Trading Economics

Ingresos

215M

Ventas

-1.1B

785M

P/B

Media del Sector

31.374

63.778

Rentabilidad por dividendo

0.77

Margen de beneficio

11.32

Empleados

14,147

EBITDA

-247M

161M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+15.58% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.77%

2.39%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

14B

Apertura anterior

117.03

Cierre anterior

119

Noticias sobre sentimiento de mercado

By Acuity

19%

81%

36 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

BioMerieux Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

3 abr 2025, 23:04 UTC

Principales Noticias

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 abr 2025, 22:40 UTC

Principales Movimientos del Mercado

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 abr 2025, 22:18 UTC

Adquisiciones, fusiones, absorciones

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 abr 2025, 18:51 UTC

Adquisiciones, fusiones, absorciones

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 abr 2025, 23:43 UTC

Charlas de Mercado

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 abr 2025, 23:41 UTC

Charlas de Mercado

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 abr 2025, 22:22 UTC

Adquisiciones, fusiones, absorciones

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 abr 2025, 22:21 UTC

Adquisiciones, fusiones, absorciones

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 abr 2025, 21:43 UTC

Principales Noticias
Ganancias

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 abr 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

3 abr 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 abr 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

3 abr 2025, 20:43 UTC

Charlas de Mercado

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 abr 2025, 20:34 UTC

Principales Noticias

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 abr 2025, 20:23 UTC

Principales Noticias

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 abr 2025, 20:15 UTC

Adquisiciones, fusiones, absorciones

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 abr 2025, 19:55 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 abr 2025, 19:55 UTC

Charlas de Mercado

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 abr 2025, 19:21 UTC

Charlas de Mercado

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 abr 2025, 19:15 UTC

Charlas de Mercado

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 abr 2025, 18:45 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 abr 2025, 18:45 UTC

Charlas de Mercado

Gold Drops In Tariff Fallout -- Market Talk

3 abr 2025, 18:39 UTC

Charlas de Mercado

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 abr 2025, 18:38 UTC

Principales Noticias

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 abr 2025, 18:30 UTC

Principales Noticias

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 abr 2025, 18:20 UTC

Charlas de Mercado

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 abr 2025, 18:18 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 abr 2025, 18:17 UTC

Charlas de Mercado

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 abr 2025, 18:04 UTC

Charlas de Mercado

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 abr 2025, 17:55 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparación entre iguales

Cambio de precio

BioMerieux Esperado

Precio Objetivo

By TipRanks

15.58% repunte

Estimación a 12 meses

Media 133.5 EUR  15.58%

Máximo 140 EUR

Mínimo 129 EUR

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioMerieux Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

6

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

115.8 / 117.5Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

36 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de BioMerieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.